aTYR PHARMA INC (ATYR) shareholders
Close on Nov 17, 2026Market cap $489.46MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Federated Hermes, Inc. Joint filing with Voting Shares Irrevocable Trust (8.68%), Thomas R. Donahue (8.68%) and 2 more | 8,509,678 | 8.68% | 13G (passive) amendment | Jun 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (6.10%) | 5,935,900 | 6.10% | 13G (passive) amendment | May 29, 2026 |
| Ann C. Donahue Joint filing with Federated Hermes, Inc. (5.06%), Voting Shares Irrevocable Trust (5.06%) and 2 more | 4,965,414 | 5.06% | 13G (passive) amendment | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ATYR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 8,509,678 | 8.68% | $5.08M | −2,000,000 | 0.01% |
| Vanguard Capital Management LLC | 3,808,091 | 3.88% | $2.27M | −4,041 | 0.00% |
| Kalehua Capital Management LLC | 3,576,334 | 3.65% | $2.13M | New | 0.68% |
| Gsa Capital Partners Llp | 3,454,863 | 3.52% | $2.06M | +1,770,277 | 0.13% |
| Aqr Capital Management LLC | 2,610,548 | 2.66% | $1.56M | +2,114,530 | 0.00% |
| FMR LLC | 2,471,418 | 2.52% | $1.47M | −12,235,425 | 0.00% |
| BlackRock, Inc. | 1,827,332 | 1.86% | $1.09M | −4,616,572 | 0.00% |
| Jane Street Group, LLC | 1,721,297 | 1.75% | $1.03M | +1,672,795 | 0.00% |
| UBS Group AG | 1,531,151 | 1.56% | $914.10K | −2,336,062 | 0.00% |
| Morgan Stanley | 1,343,636 | 1.37% | $801.88K | +118,169 | 0.00% |
| Two Sigma Investments, LP | 1,245,147 | 1.27% | $743.10K | +100,582 | 0.00% |
| Citadel Advisors LLC | 1,242,067 | 1.27% | $741.27K | +1,194,695 | 0.00% |
| Geode Capital Management, LLC | 1,177,020 | 1.20% | $702.73K | −1,208,465 | 0.00% |
| Susquehanna International Group, Llp | 747,039 | 0.76% | $445.83K | −119,705 | 0.00% |
| Millennium Management LLC | 656,051 | 0.67% | $391.53K | −985,195 | 0.00% |
| Goldman Sachs Group Inc | 641,208 | 0.65% | $382.67K | +357,972 | 0.00% |
| Vanguard Fiduciary Trust Co | 576,125 | 0.59% | $343.95K | −75,707 | 0.00% |
| State Street Corp | 494,951 | 0.50% | $295.39K | −1,259,448 | 0.00% |
| Marshall Wace, Llp | 368,120 | 0.38% | $220.87K | +230,002 | 0.00% |
| XTX Topco Ltd | 226,678 | 0.23% | $135.28K | +115,255 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 90 | 41M | 41.4% | 16 / 29 | 30 / 35 | 12M | 28M |
| Q1 2026 | 111 | 56M | 57.1% | 36 / 26 | 32 / 8 | 11M | 5M |
| Q4 2025 | 84 | 55M | 55.9% | 16 / 24 | 25 / 34 | 6M | 13M |
| Q3 2025 | 103 | 62M | 63.3% | 34 / 33 | 25 / 39 | 15M | 20M |
| Q2 2025 | 110 | 66M | 67.8% | 52 / 25 | 24 / 29 | 12M | 8M |
| Q1 2025 | 87 | 62M | 63.0% | 26 / 36 | 14 / 16 | 13M | 6M |
| Q4 2024 | 77 | 55M | 56.0% | 30 / 24 | 12 / 8 | 13M | 5M |
| Q3 2024 | 56 | 48M | 48.8% | 15 / 15 | 12 / 5 | 4M | 6M |
| Q2 2024 | 47 | 51M | 52.1% | 8 / 22 | 11 / 17 | 12M | 3M |
| Q1 2024 | 56 | 42M | 42.7% | 15 / 21 | 10 / 5 | 5M | 5M |
| Q4 2023 | 46 | 41M | 42.1% | 9 / 15 | 10 / 3 | 9M | 4M |
| Q3 2023 | 40 | 37M | 37.4% | 7 / 6 | 18 / 8 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
101 funds held ATYR in Q1 2026, 25% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ATYR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 4,367,290 | 4.45% | $2.12M | 0.04% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 4,216,832 | 4.30% | $2.29M | 0.00% | May 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 4,061,288 | 4.14% | $1.97M | 0.07% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,650,788 | 2.70% | $1.58M | 0.00% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,754,594 | 1.79% | $951.87K | 0.02% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 1,054,556 | 1.08% | $629.36K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 550,058 | 0.56% | $298.41K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 488,823 | 0.50% | $265.19K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 168,117 | 0.17% | $91.20K | 0.00% | May 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 146,027 | 0.15% | $87.15K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 145,359 | 0.15% | $78.86K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 85,881 | 0.09% | $46.59K | 0.00% | May 31, 2026 |
| Federated Hermes Kaufmann Fund II | 81,100 | 0.08% | $48.40K | 0.04% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 66,669 | 0.07% | $36.17K | 0.00% | May 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 66,034 | 0.07% | $39.41K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sanjay Shukla | President and CEO, Director | 153,553 | 0.16% | Feb 4, 2026 |
| Brandon Yaras | Chief Financial Officer | – | – | Oct 1, 2026 |
| Jill Marie Broadfoot | Chief Financial Officer | 37,296 | 0.04% | Feb 4, 2026 |
| Nancy Denyes | General Counsel | 33,124 | 0.03% | Feb 4, 2026 |
| Paul Schimmel | Director | 2,201,056 | 2.24% | May 28, 2026 |
| Jane A. Gross | Director | 9,750 | 0.01% | May 13, 2026 |
| Sara Zaknoen | Director | 6,000 | 0.01% | May 13, 2026 |
| Svetlana Lucas | Director | 6,000 | 0.01% | May 13, 2026 |
| Timothy Coughlin | Director | 56,000 | 0.06% | May 13, 2026 |
| Eric Benevich | Director | – | – | May 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Paul Schimmel Director | May 27, 2026 | Buy | +100,000 | $0.50 | $50.00K | 779,143 |
| Nancy Denyes General Counsel | Feb 4, 2026 | Sale | −1,118 | $0.98 | $1.10K | 33,124 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 4, 2026 | Sale | −1,558 | $0.98 | $1.53K | 37,296 |
| Sanjay Shukla President and CEO, Director | Feb 4, 2026 | Sale | −3,745 | $0.98 | $3.67K | 153,553 |
| Nancy Denyes General Counsel | Feb 3, 2026 | Option exercise | +2,687 | – | – | 34,242 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 3, 2026 | Option exercise | +3,750 | – | – | 38,854 |
| Sanjay Shukla President and CEO, Director | Feb 3, 2026 | Option exercise | +10,375 | – | – | 157,298 |
| Paul Schimmel Director | Oct 9, 2025 | Buy | +317,999 | $0.94 | $298.92K | 1,413,023 |
| Paul Schimmel Director | Oct 8, 2025 | Buy | +682,001 | $0.90 | $613.80K | 1,095,024 |
| Jane A. Gross Director | Mar 17, 2025 | Buy | +3,750 | $4.00 | $15.00K | 9,750 |
| Nancy Denyes General Counsel | Feb 4, 2025 | Sale | −899 | $3.78 | $3.40K | 26,555 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 4, 2025 | Sale | −1,254 | $3.78 | $4.74K | 31,763 |
| Nancy Denyes General Counsel | Feb 3, 2025 | Option exercise | +2,687 | – | – | 27,454 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 3, 2025 | Option exercise | +3,750 | – | – | 33,017 |
| Sanjay Shukla President and CEO, Director | Feb 3, 2025 | Option exercise | +10,375 | – | – | 146,923 |
| Paul Schimmel Director | Jul 24, 2024 | Buy | +52,300 | $1.93 | $100.94K | 413,023 |
| Paul Schimmel Director | Jul 23, 2024 | Buy | +6,648 | $1.82 | $12.10K | 360,723 |
| Paul Schimmel Director | Jul 22, 2024 | Buy | +41,052 | $1.74 | $71.43K | 354,075 |
| Nancy Denyes General Counsel | Jun 5, 2024 | Buy | +5,000 | $1.86 | $9.30K | 22,267 |
| Sanjay Shukla President and CEO, Director | May 31, 2024 | Buy | +20,000 | $1.81 | $36.20K | 136,548 |
| Jill Marie Broadfoot Chief Financial Officer | May 31, 2024 | Buy | +5,000 | $1.79 | $8.95K | 27,960 |
| Timothy Coughlin Director | May 30, 2024 | Buy | +50,000 | $1.75 | $87.50K | 56,000 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 6, 2024 | Sale | −1,590 | $1.69 | $2.69K | 20,821 |
| Nancy Denyes General Counsel | Feb 5, 2024 | Option exercise | +2,688 | – | – | 14,767 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 5, 2024 | Option exercise | +3,750 | – | – | 22,411 |
| Sanjay Shukla President and CEO, Director | Feb 5, 2024 | Option exercise | +10,375 | – | – | 116,548 |
| Sanjay Shukla President and CEO, Director | Dec 12, 2023 | Buy | +12,000 | $1.18 | $14.16K | 106,173 |
| Sanjay Shukla President and CEO, Director | Dec 11, 2023 | Buy | +3,000 | $1.17 | $3.51K | 94,173 |
| Sanjay Shukla President and CEO, Director | Nov 13, 2023 | Buy | +13,578 | $1.11 | $15.07K | 91,173 |
| Sanjay Shukla President and CEO, Director | Nov 10, 2023 | Buy | +1,422 | $1.14 | $1.62K | 77,595 |
| Sanjay Shukla President and CEO, Director | Jul 28, 2023 | Buy | +15,000 | $2.01 | $30.15K | 76,173 |
| Timothy Coughlin Director | May 17, 2023 | Gift | −6,000 | – | – | 0 |
| Timothy Coughlin Director | May 17, 2023 | Gift | +6,000 | – | – | 6,000 |
| Paul Schimmel Director | May 10, 2023 | Buy | +200,000 | $2.25 | $450.00K | 313,023 |
| Svetlana Lucas Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 6,000 |
| John K. Clarke Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 19,797 |
| Jane A. Gross Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 6,000 |
| Paul Schimmel Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 8,890 |
| Sara Zaknoen Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 6,000 |
| Timothy Coughlin Director | Apr 26, 2023 | Option exercise | +6,000 | – | – | 6,000 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 6, 2023 | Sale | −1,566 | $2.36 | $3.70K | 15,460 |
| Sanjay Shukla President and CEO, Director | Feb 3, 2023 | Option exercise | +10,375 | – | – | 61,173 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 3, 2023 | Option exercise | +3,750 | – | – | 17,026 |
| Nancy Denyes General Counsel | Feb 3, 2023 | Option exercise | +2,688 | – | – | 7,079 |
| Sanjay Shukla President and CEO, Director | Nov 21, 2022 | Buy | +10,000 | $2.14 | $21.40K | 50,798 |
| Sanjay Shukla President and CEO, Director | Jul 1, 2022 | Buy | +15,000 | $2.88 | $43.20K | 40,798 |
| Jill Marie Broadfoot Chief Financial Officer | Jan 13, 2022 | Buy | +1,923 | $6.75 | $12.98K | 12,112 |
| Sanjay Shukla President and CEO, Director | Jan 7, 2022 | Buy | +5,000 | $6.76 | $33.80K | 25,798 |
| Sanjay Shukla President and CEO, Director | Nov 15, 2021 | Buy | +2,500 | $8.58 | $21.45K | 20,798 |
| Paul Schimmel Director | Sep 20, 2021 | Gift | +250,000 | – | – | 679,143 |
| Paul Schimmel Director | Sep 20, 2021 | Buy | +250,000 | $8.00 | $2.00M | 252,890 |
| Paul Schimmel Director | Sep 20, 2021 | Gift | −250,000 | – | – | 2,890 |
| John K. Clarke Director | May 21, 2021 | Sale | −2,500 | $4.34 | $10.85K | 108,083 |
| Sanjay Shukla President and CEO, Director | May 18, 2021 | Buy | +10,000 | $4.01 | $40.10K | 18,298 |
| Paul Schimmel Director | May 18, 2021 | Buy | +50,000 | $3.98 | $199.00K | 113,023 |
| Sanjay Shukla President and CEO, Director | Feb 9, 2021 | Sale | −778 | $7.66 | $5.96K | 8,298 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 9, 2021 | Sale | −390 | $7.66 | $2.99K | 9,833 |
| Sanjay Shukla President and CEO, Director | Feb 6, 2021 | Option exercise | +1,785 | – | – | 9,076 |
| Jill Marie Broadfoot Chief Financial Officer | Feb 6, 2021 | Option exercise | +892 | – | – | 10,223 |
| John K. Clarke Director | Sep 2, 2020 | Sale | −7,260 | $4.01 | $29.11K | 110,583 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of aTYR PHARMA's stock actually held short. Settlement fails (shares not delivered on time) peaked at 13,043 shares on Sep 18, 2026 over the last 90 days.
See a number that looks wrong?